Skip to content
Featured
FEATURED | January 24, 2025

The Melanoma Research Foundation Announces Rebrand...

Washington, DC (January 27, 2025) – The Melanoma Research Foundation (MRF), the largest independent organization devoted to melanoma, is excited to announce the official ...

3 Minute Read
Melanoma News |
February 28, 2024

FDA Announces Approval of TIL Therapy or AMTAGVI�...

On February 16 the FDA announced the approval of TIL therapy or AMTAGVI™ the first cellular therapy indicated for the treatment of adult patients with cutaneous (skin) me...

1 Minute Read
Melanoma News |
February 16, 2024

National Caregiver’s Day – Nick Doble ...

Guest blog post by Nick Doble, ocular melanoma caregiver and MRF supporter: “Being a caregiver is hard, and it’s not something you sign up for. It’s full of compl...

4 Minute Read
Melanoma News |
November 20, 2023

“Options Bring Hope” Research Grant, d...

For the past two years, the Miller Family, along with their circle of friends and the unwavering support of their community, embarked on a remarkable journey to shed light ...

2 Minute Read
Melanoma News |
August 31, 2022

Iovance Biotherapeutics Initiates Biologics Licens...

First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration with Complete BLA Submission on Track for Fourth Quarter 2022 On August 25, Iovance Biothe...

1 Minute Read
Melanoma News |
April 8, 2022

The MRF Applauds FDA’s Commitment to Propose...

The MRF is proud to join our fellow members of the National Council on Skin Cancer Prevention (NCSCP) in urging the U.S. Food and Drug Administration (FDA) to finalize prop...

1 Minute Read
Melanoma News |
March 18, 2022

FDA Grants Investigational New Drug Application fo...

On March 15, the U.S. Food and Drug Administration (FDA) granted Iovance Biotherapeutics, Inc. an Investigational New Drug Application (IND) for IOV-4001, its first geneti...

1 Minute Read
Melanoma News |
February 11, 2022

The First FDA Approved Treatment for Metastatic Uv...

On January 26, 2022, the U.S. Food and Drug Administration announced the approval of KIMMTRAK (tebentafusp-tebn), the first and only FDA-approved treatment for metastatic u...

2 Minute Read
Melanoma News |
February 9, 2022

A Monumental First Step in Uveal Melanoma

Guest blog post by Keith T. Flaherty, MD, Associate Professor of Medicine at Harvard Medical School, Director of Developmental Therapeutics at Massachusetts General Hospita...

4 Minute Read
Melanoma News |
August 30, 2021

MRF’s 25th Anniversary: Learning More about ...

For our 25th anniversary, we share a guest blog from Vito Rebecca, PhD from Johns Hopkins University Bloomberg School of Public Health: As a scientist, a translational rese...

3 Minute Read
Melanoma News |
April 23, 2021

MRF’s 25th Anniversary: Encouraging Progress...

For our 25th anniversary, we share a guest blog from Richard D. Carvajal, MD from Columbia University Herbert Irving Comprehensive Cancer Center and recipient of the CURE O...

4 Minute Read
Melanoma News |
March 12, 2021

Leading Skin Cancer Organizations Urge the FDA to ...

WASHINGTON, DC – The Melanoma Research Foundation (MRF) recently signed– on to a letter from the National Council of Skin Cancer Prevention (NCSCP) urging ...

1 Minute Read
Melanoma News |
March 11, 2021

FDA Grants Alkermes Orphan Drug Designation for th...

WASHINGTON, DC – The U.S. Food and Drug Administration (FDA) has recently granted orphan drug designation for the treatment of mucosal melanoma to Alkermes’ investi...

1 Minute Read

Feb 18, 2025

Ask the Expert: Stronger Together – Navigating Melanoma Caregiving and Support Services

Feb 21, 2025 - Feb 23, 2025

Pediatric Melanoma Family Retreat Weekend

Feb 18, 2025

Ask the Expert: Stronger Together – Navigating Melanoma Caregiving and Support Services

Feb 21, 2025 - Feb 23, 2025

Pediatric Melanoma Family Retreat Weekend

Mar 02, 2025 - Mar 04, 2025

2025 Advocacy Days

Apr 05, 2025

Fred Hutch Cancer Center Patient Symposium

Apr 07, 2025

UNC Lineberger Comprehensive Cancer Center Patient Symposium

All Events